Interestingly, parallel increases in plasma adiponectin levels and histological improvement of NASH were also observed in a systematic review of four randomized clinical trials, providing data on 187 patients with NASH treated up to 12 months [40]. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatohepatitis.